Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.91 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.91 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9420125 | 0.99 | PTGS2 (0.89) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL7704620 | 0.99 | PTGS2 (0.89) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| Tebufelone SCHEMBL43674 | 0.95 | PTGS2 (1.00) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL7701417 | 0.89 | ALOX5 (0.83) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL9860963 | 0.88 | PTGS2 (0.85) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL9860870 | 0.87 | PTGS2 (0.84) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL10548270 | 0.87 | PTGS2 (0.70) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL10551397 | 0.83 | PTGS2 (0.76) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL9004912 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1ALOX5KMT2AMEN1 | |
| SCHEMBL9359469 | 0.81 | PTGS2 (0.66) | PTGS2PTGS1ALOX5KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218437-B1 | ADMINISTERING A THERAPEUTIC AMOUNT OF DI-TERT-BUTYLPHENOL DERIVATIVE TO SUBJECT UNDER CONDITIONS SUCH THAT SAID SYMPTOMS ARE DIMINISHED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-04-17 | — | — | US | claimed |
| US-4708966-A | SUBSTITUTED DI-TERT-BUTYL PHENOL DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1987-11-24 | — | — | US | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-6420428-B1 | TREATING HEPATITIS C AND HEPATIC FIBROSIS USING 2,6-DI-TERT-BUTYLPHENOL DERIVATIVES; EFFECTIVE IN SUBJECTS WITH INTERFERON INSUSCEPTIBILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-07-16 | — | — | US | disclosed |
| US-6369097-B1 | Treatment and prevention of hepatic disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-09 | — | — | US | disclosed |
| US-6348493-B1 | TREATMENT OF HEPATITIS C BY ADMINISTERING 2,6-DI-TER-BUTYLPHENOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-02-19 | — | — | US | disclosed |
| US-6218437-B1 | ADMINISTERING A THERAPEUTIC AMOUNT OF DI-TERT-BUTYLPHENOL DERIVATIVE TO SUBJECT UNDER CONDITIONS SUCH THAT SAID SYMPTOMS ARE DIMINISHED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-04-17 | — | — | US | disclosed |
| WO-2001021166-A1 | TREATMENT AND PREVENTION OF HEPATIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-03-29 | — | — | WO | disclosed |
| EP-0251408-B1 | NOVEL ANTI-INFLAMMATORY AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | THE PROCTER & GAMBLE COMPANY (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4708966-A | SUBSTITUTED DI-TERT-BUTYL PHENOL DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1987-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | PTGS2 99/4885PTGS1 76/4885ALOX5 25/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | PTGS2 99/4885PTGS1 76/4885ALOX5 25/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | PTGS2 1253/4885PTGS1 593/4885ALOX5 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.